Skip to main content
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. — Investor Relations & Filings

Ticker · DNLI ISIN · US24823R1059 LEI · 549300ZTQ2HO18L3Q830 US Manufacturing
Open in API
Filings indexed 749 across all filing types
Latest filing 2022-06-07 Director's Dealing
Country US United States of America
Listing US DNLI

About Denali Therapeutics Inc.

https://www.denalitherapeutics.com

Denali Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases, lysosomal storage disorders, and other serious illnesses. The company's core scientific strategy centers on its proprietary Transport Vehicle™ (TV) platform, which is engineered to transport large therapeutic molecules, such as antibodies and enzymes, across the blood-brain barrier. This technology is designed to overcome a primary obstacle in treating diseases of the central nervous system. Denali's pipeline comprises a portfolio of investigational drug candidates that leverage this platform to target the underlying genetic and biological pathways of complex diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-06-07 English
FORM 4
Director's Dealing
2022-06-07 English
FORM 4
Director's Dealing
2022-06-07 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 2, 2022, by Denali Therapeutics Inc. It reports the results of the annual meeting of stockholders, including voting outcomes on director elections, appointment of the independent auditor, and advisory vote on executive compensation. The content focuses on the submission of matters to a vote of security holders, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements. The document is about the official results from shareholder votes at the annual meeting, not the full annual report or proxy statement itself. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements). The document length is 4618 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report publication.
2022-06-03 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 5, 2022, by Denali Therapeutics Inc. It announces the issuance of a press release with financial results for the first quarter ended March 31, 2022. The document itself does not contain the financial results but references an attached press release (Exhibit 99.1) that contains the financial results. The text explicitly states that the information is furnished and not filed, and the press release is incorporated by reference. The document length is 3476 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing the earnings release but does not contain substantive financial data itself. It is not the earnings release (ER) itself, nor an annual or interim report. Therefore, the appropriate classification is RNS with high confidence.
2022-05-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.